Arcutis Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Arcutis Biotherapeutics Inc ARQT.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -42 cents. The mean expectation of eight analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -20 cents to -11 cents per share.

• Revenue rose 164.1% to $81.50 million from a year ago; analysts expected $73.69 million.

• Arcutis Biotherapeutics Inc's reported EPS for the quarter was a loss of 13 cents​.

• The company reported a quarterly loss of $15.54 million.

• Arcutis Biotherapeutics Inc shares had risen by 9.3% this quarter and gained 10.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 7.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $20.00, about 23.4% above its last closing price of $15.33

This summary was machine generated from LSEG data August 6 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)